CAS: 54221-96-4; 6-Methoxypicolinaldehyde

相似化合物

26893-73-2 26256-72-4 83621-01-6

上下游产品

6-bromo-2-methoxypyridine N,N-dimethyl-formamide 2,6-Dibromopyridine dicobalt °Ctacarbonyl 6-Methoxy-3-methyl-2-pyridinealdehyde 6-methoxy-5-methyl-2-pyridinecarboxaldehyde (E)-N-((6-methoxypyridin-2-yl)methylene)-2,4,6-trimethylbenzenamine 2-methoxy-6-[2-(5-methoxy-2-nitrophenyl)-vinyl]pyridine

2,6-二溴吡啶置于正丁基锂体系中,用 四氢呋喃,甲醇,正己烷,N,N-二甲基甲酰胺 作为反应溶剂,化学反应 3.5H,反应生成 6-甲氧基吡啶-2-甲醛
参考文献:α-吡啶酮及其衍生物的制备及其抗氧化活性.
标题:α-吡啶酮及其衍生物的制备及其抗氧化活性.
摘要:着眼于作为新型抗氧化烯二醇的先导化合物的α-吡啶酮(1,2-二(2-吡啶基)-1,2-乙二醇),我们合成了5,5'-或6,6'-Bis-来自二取代吡啶的1的取代衍生物.通过清除dpph(1,1-二苯基-2-吡啶基肼基自由基)和抑制脂质过氧化作用来评估1及其合成衍生物2-7的抗氧化活性.在dpph分析中,1表现出比抗坏血酸强的活性,而5,5'-二甲基-(5)或5,5'-二甲氧基取代的衍生物(6)表现出比1更强的活性. α-吡啶酮类化合物的活性与其氧化电位相关,因此与烯二醇的电子密度相关.图5和图6有效抑制大鼠肝微粒体/叔丁基氢过氧化物系统中的脂质过氧化.所以,
DOI:10.1016/j.Bmc.2005.07.065

专利信息

专利号:US-2024309003-A1
优先权日:2021-05-04
标题 :Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN; PANDYA BHAUMIK; KAPLAN ALAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:CN-113603687-A
优先权日:2021-08-02
标 题:A new method for the synthesis of cyano-substituted imidazo[1,5-a]pyridines

专利号:US-9359298-B2
优先权日:2011-12-23
标题:Cajanine structure analogous compound, preparation method and use
发明人：LI ZHUORONG; JI XINGYUE; Xue situ; ZHENG GUANGHUI; LI YUHUAN; TAO PEIZHEN; JIANG JIANDONG
权利人:INST MED BIOTECHNOLOGY CAMS
摘要:Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

专利号:CN-102875452-A
优先权日:2012-10-22
标题:A kind of chemical synthesis method of 2-(2'-pyridyl) cyclopropanecarboxylic acid derivative

专利号:EP-1040098-B1
优先权日:1997-12-17
标题:Integrin receptor antagonists
发明人：ASKEW BEN C; COLEMAN PAUL J; DUGGAN MARK E; HALCZENKO WASYL; HARTMAN GEORGE D; HUNT CECILIA; HUTCHINSON JOHN H; MEISSNER ROBERT S; PATANE MICHAEL A; SMITH GARRY R; WANG JIABING
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alpha nu beta 3, alpha nu beta 5, and/or alpha nu beta 6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.

专利号:US-6784190-B2
优先权日:1997-12-17
标 题 :Integrin receptor antagonists
发明人：ASKEW BEN C; COLEMAN PAUL J; DUGGAN MARK E; HALCZENKO WASYL; HARTMAN GEORGE D; HUNT CECILIA A; HUTCHINSON JOHN H; MEISSNER ROBERT S; PATANE MICHAEL A; SMITH GARRY R; WANG JIABING
权利人:MERCK & CO INC
摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alphavbeta3, alphavbeta5, and/or alphavbeta6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.